ArticleNature communications2018
Characterising the phenotypic evolution of circulating tumour cells during treatment.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma.Science advances · 2020Trial
- Recent advances in nanomaterial-based optical biosensors and their biomedical and biopharmaceutical applications.Journal of pharmaceutical analysis · 2026Review
- Precision oncology through SERS: emerging approaches for improved cancer diagnosis and prognosis.Nanomedicine (London, England) · 2025Article
- Detecting microsatellite instability in cancerChemical science · 2025Article
- Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate.NPJ precision oncology · 2025Article
- Circulating tumor cells: from new biological insights to clinical practice.Signal transduction and targeted therapy · 2024Review
- SERS biosensors for liquid biopsy towards cancer diagnosis by detection of various circulating biomarkers: current progress and perspectives.Nano convergence · 2024Review
- SERS in 3D cell models: a powerful tool in cancer research.Chemical Society reviews · 2024Review
- Novel genetic assessments for cancer patients: where does medical imaging stand in the future of personalised medicine?Journal of medical radiation sciences · 2024Article
- Quantification of capture efficiency, purity, and single-cell isolation in the recovery of circulating melanoma cells from peripheral blood by dielectrophoresis.Lab on a chip · 2023Article
- Liquid Biopsies in Lung Cancer.Cancers · 2023Review
- Phenotypic maps for precision medicine: a promising systems biology tool for assessing therapy response and resistance at a personalized level.Frontiers in network physiology · 2023Article
- Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.Frontiers in cell and developmental biology · 2023Review
- New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells.Cancer cell international · 2022Article
- SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment.Exploration (Beijing, China) · 2022Article
- The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer.Dynamic games and applications · 2022Review
- Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering.Biosensors · 2021Review
- Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma.Cancers · 2021Article
- Circulating tumor cell profiling for precision oncology.Molecular oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-time monitoring of cancer cells' phenotypic evolution during therapy can provide vital tumour biology information for treatment management. Circulating tumour cell (CTC) analysis has emerged as a useful monitoring tool, but its routine usage is restricted by either limited multiplexing capability or sensitivity. Here, we demonstrate the use of antibody-conjugated and Raman reporter-coated gold nanoparticles for simultaneous labelling and monitoring of multiple CTC surface markers (named as "cell signature"), without the need for isolating individual CTCs. We observe cell heterogeneity and phenotypic changes of melanoma cell lines during molecular targeted treatment. Furthermore, we follow the CTC signature changes of 10 stage-IV melanoma patients receiving immunological or molecular targeted therapies. Our technique maps the phenotypic evolution of patient CTCs sensitively and rapidly, and shows drug-resistant clones having different CTC signatures of potential clinical value. We believe our proposed method is of general interest in the CTC relevant research and translation fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.